An interventional study of Decision Aid in Carotid Artery Stenoses and Carotid Artery Stenosis Asymptomatic, sponsored by Dartmouth-Hitchcock Medical Center. Not yet recruiting at 1 site in United States. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Dartmouth-Hitchcock Medical Center · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 84 studies in Carotid Stenosis with a site in United States — 6 open to participants now, 13 under way, none of them phase 3. Carotid Stenosis · United States.
Among the 84 studies in Carotid Stenosis with a site in United States, this one is the 31st largest by planned enrollment of the 53 interventional ones that give a count, is one of 2 that started in 2026, is one of 29 with no phase, reaches primary completion later than 9 of the 12 other live ones, and was the 84th registered.
368 studies on the registry are indexed under Carotid Stenosis; 87 are open to participants now.
Browse Carotid Stenosis studies →6 of the 84 studies in Carotid Stenosis with a site in United States are open now. Recruiting first, the newest first:
InspireMD · Sites in United States
Ages 18–79
Mayo Clinic · Sites in United States
Ages 18+
VA Office of Research and Development · Sites in United States
Ages 18–89 · Healthy volunteers
University of California, San Diego · Sites in United States
Ages 18+
Vibrant Medical Ltd. · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 61 Carotid Stenosis studies recruiting now, 39 (64%) set no upper age limit and none (0%) stop at 75 or younger; 4 take children under 18; 4 take healthy volunteers.
This study: 65 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
84 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 10 · Phase 3 7 · Phase 4 5
First in 1993; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 102 across 192 interventional studies indexed under Carotid Stenosis.
Median enrollment 69 across the 53 interventional studies, 114 across the 31 observational. Of the 60 that completed or were terminated, 22 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 84 have an industry lead sponsor. The 10 most frequent:
Dartmouth-Hitchcock Medical Center is the lead sponsor of 489 studies on the registry; 69 are open to participants now.
Of its 31 completed or terminated interventional studies of FDA-regulated products, 21 (68%) have results posted.
Dartmouth-Hitchcock Medical Center has 1 study filed under Carotid Stenosis — fewer than ten, so there is no comparison to draw.
4 of the studies in Carotid Stenosis with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06653387InspireMDA Single-arm, Pivotal Study to Evaluate Acute Device and Technical Success of the CGuard Prime Carotid Stent System When Used in Conjunction to the ENROUTE Transcarotid Neuroprotection System in Patients Undergoing Carotid Artery Stenting Via the Transcarotid Artery Revascularization Approach | 2026-11-20 |
| NCT07851389Vibrant Medical Ltd.A First-in-Human Feasibility Study of the Vibrant Stroke Detection Technology During Carotid Endarterectomies | 2027-03 |
| NCT04063709University of North Carolina, Chapel HillTranscutaneous ARFI Ultrasound for Differentiating Carotid Plaque With High Stroke Risk | 2027-08 |
| NCT05465122Mayo ClinicCREST-2 Long-term Observational Extension Study | 2027-08-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 84 studies in Carotid Stenosis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Carotid artery stenosis is a common cause of ischemic stroke in the U.S. and disproportionately affects older adults. Patients with carotid artery stenosis face a complex set of decisions when choosing a treatment strategy. Patients must choose among surveillance with medical therapy alone, versus medical therapy plus one of three different procedures. Each treatment option has different levels of evidence to support it, some of which are decades old. Each procedural option has different expected periprocedural courses, different recoveries, and different cardiovascular risks. This challenging decision is amplified among older adults, where decisional values are often different from younger patients traditionally studied in randomized or observational studies. A decision aid could assist patients and providers who are navigating this decision, but no decision aid currently exists that includes all the contemporary carotid artery stenosis treatment options. In addition, as of October 2023, participation in a shared decision-making conversation is a Medicare-mandated component of carotid stenosis care, with reimbursement for procedures predicated on the documentation of the conversation with the patient.
The objective of this project is to conduct a single arm open label trial to test the feasibility of using a paper-based decision aid for patients considering carotid revascularization. The investigators will conduct a feasibility trial using the decision aid on older adults who are considering carotid revascularization. The investigators will recruit 50 participants aged 65 or older from the vascular surgery clinic and administer the decision aid. The investigators will purposively sample at least 10 participants that are age 80 or older. Primary outcomes will center on feasibility, and secondary outcomes will center on decisional conflict and regret.
The primary outcomes of this single arm open label feasibility trial are focused on feasibility, and the secondary outcomes will provide data to inform a subsequent R01 study design.
Exposure: The decision aid
Setting: The investigators will sample newly referred and longitudinally treated patients from the Dartmouth Health Vascular Clinic who are being treated for carotid artery stenosis and who are considering carotid revascularization.
Sampling strategy: The investigators will enroll 50 patient-participants. The investigators will review the clinic schedules of the 18 providers each day in clinic and screen them for patients being seen for carotid artery stenosis. The investigators will then discuss with the providers in clinic that day whether any of the patients they are seeing may be considered for carotid revascularization and whether that respective patient would be appropriate for and have the capacity to utilize a decision aid. The investigators will purposively sample a minimum of 10 participants who are aged 80 and older to ensure adequate representation of this age group. Patients with carotid stenosis routinely have a high burden of comorbidities including hypertension, diabetes, coronary disease, kidney disease, and smoking. Patients treated in the Dartmouth Vascular Clinic are representative of this population and will allow us to sample a cohort with multiple comorbidities. Patients meeting the inclusion and exclusion criteria and felt to be appropriate for a decision aid per their treating provider will be approached in clinic to discuss the study.
Statistical analysis:
Outcome 1: The investigators will measure the mean and standard deviation of the time of the clinic visit. The investigators will calculate the visit time from the time of patient check in until the completion of the clinic visit, as assessed by a direct observer. The investigators will compare this to baseline time measurements recorded in the electronic health record for a random sample of 50 carotid stenosis patients meeting the same inclusion / exclusion criteria in the past 3 months.
Outcome 2: The investigators will conduct semi-structured interviews with 10 patients to follow up on the findings from the surveys above. These will be semi-structured interviews that are designed to assess whether the tradeoffs for each decision aid option were understood, and whether they felt that the decision aid helped them reach their choice. The interviews will be recorded and transcribed. The constant comparative method will be used to identify codes inductively. Two independent coders will analyze the data, and then codes will be discussed and data organized. Areas of disagreement will be resolved by consensus, or, if consensus is not possible, by a third independent reviewer. The investigators will organize the codes into key domains through data reduction and interpretation, paying particular attention to the frequency of specific ideas / codes mentioned by participants, and how many participants mentioned them.
The investigators will administer a similar survey to their treating providers within 1 week of the clinic visit. The results of the Likert surveys will be converted to a 5-point scale and the mean and median response will be computed with 95% confidence intervals. The investigators will additionally conduct semi-structured interviews with treating providers to determine feasibility of decision aid use in routine practice.
Secondary outcomes: The investigators will administer a validated decisional conflict scale and decisional regret scale before and after administration of the decision aid. The investigators will use the low literacy version to account for the high prevalence of low literacy in older adults. The investigators will analyze the results according to the validated methods for that survey and compare the before and after results. The investigators will additionally measure the actual treatment decision made by the patient and report this unadjusted. The investigators will finally measure knowledge-based questions that will be administered before and after patients are given the decision aid.
Sample size considerations: For outcome 1, given a sample size of 50 normally distributed outcomes, this will result in sample size with 95% confidence intervals with half widths of 0.32 standard deviation of the matched visit estimates of added time for increasing to 0.34, and 0.36 with 10% and 20% missing data. Similar results hold for the Likert survey in Outcome 3.
Potential pitfalls and alternative strategies: It is possible that it may not be known whether a patient would benefit from a decision aid until the patient receives an imaging study demonstrating the severity of the patient's carotid disease, which may occur just before the patient's clinic visit. Therefore, for patients who are scheduled for a clinic visit but do not have an imaging study, the investigators will ask the vascular laboratory (where the studies are conducted) to notify study personnel once the imaging study is completed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single arm pilot feasibility study of using a decision aid for patients with asymptomatic carotid artery stenosis considering revascularization
Other: Decision Aid
The decision aid is paper-based and includes pie charts of perioperative risks and incorporates patient values and preferences about autonomy of decision making.
Time to administer the decision aid
Defined as time from clinic check-in until completion of the visit
Time frame: Assessed for up to 2 weeks, from first clinic appointment until the end of the study (5/15/28)
Understanding of the decision aid
Measured by a knowledge survey
Time frame: Assessed for up to 2 weeks, from first clinic appointment until the end of the study (5/15/28)
Decisional conflict
Measured using the validated decisional conflict scale
Time frame: Assessed for up to 2 weeks, from first clinic appointment until the end of the study (5/15/28)
Decisional regret
Measured using the validated decisional regret scale
Time frame: Assessed for up to 2 weeks, from first clinic appointment until the end of the study (5/15/28)
Actual treatment decision made
What treatment the patient actually decided on
Time frame: Assessed for up to 8 weeks
Plan to share: No — Will not share individual patient data due to confidentiality.
Start is estimated for Nov 2026; primary completion for May 2028, 18 months later.
Of 51 non-industry interventional studies with no phase under Carotid Stenosis, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 50. This study's planned 18 months is below that.
Counting every sponsor, half of 62 studies reached it within 27 months; a quarter within 19 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Dartmouth-Hitchcock Medical Center →